InVivo Therapeutics Holdings had its investigational device exemption human trial approved by the FDA for a treatment of spinal cord injuries and neurotrauma conditions. The 15-month study will test a biopolymer scaffold product, which was developed to treat patients with acute traumatic spinal cord injuries. Currently, no FDA-approved treatments exist or are in clinical trials for direct spinal cord intervention, according to the release.
More Articles on Devices:
Stryker Names William Jellison CFO
Biomet Gains Exclusive Distribution Rights to OPM OsteoFab Implants
13 Spine Devices Receive FDA 510(k) Clearance in March
More Articles on Devices:
Stryker Names William Jellison CFO
Biomet Gains Exclusive Distribution Rights to OPM OsteoFab Implants
13 Spine Devices Receive FDA 510(k) Clearance in March